Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influence of Exceptional Patient Characteristics on Everolimus Exposure

Trial Profile

Influence of Exceptional Patient Characteristics on Everolimus Exposure

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Acronyms INPRES
  • Most Recent Events

    • 27 Sep 2018 Results published in the Targeted Oncology
    • 05 Jun 2018 Results (n=44) assessing everolimus exposure and early metabolic response as predictors for treatment outcomes, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 11 Apr 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top